1Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation, 2000, 10:484-486.
2De Mey C. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics-observations with beta-adrenoceptor antagonists. Int J Clin Pharmacol Ther, 1997, 35: 453-457.
3Vanhees L, Aubert A, Fagard R, et al. Influence of beta 1- versus beta 2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol, 1986, 8: 1086-1091.
4De Mey C, Breithaupt-Grogler K, Schloos J, et al. Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. Br J Clin Pharmacol, 1994, 38: 480-483.
5Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J Card Fail, 2003, 9:429-443.
6Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol, 2000, 35: 45-50.
7Sandberg A, Abrahamsson B, Svenheden A, et al. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res, 1993, 10:28-34.
8Hansson L,Hedner T,Dahlof B.Prospective randomized open blinded end-point(PROBE)study.A novel design for intervention trials.Prospective Randomized Open Blinded End-Point.Blood Press,1992,1:113-119.
9Metra M,Nodari S,D′Aloia A,et al.Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure.Eur Heart J,1998,19(Suppl B):B25-B35.
10Packer M,Colucci WS,Sackner-Bernstein JD,et al.Double-blind,placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure.The PRECISE Trial.Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
